Home / Stocks / Jubilant Pharmova Ltd
JUBLPHARMA

Jubilant Pharmova Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹933.25

Change

-0.35 (-0.04%)

Open

₹933.0

Prev. Close

₹933.6

Day High

₹937.75

Day Low

₹914.0

Volume Analysis

Traded

191,837

Delivered

107,238

Delivery %

55.9%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (6.53%)
  • •Promoter holding is falling

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹966.41 ₹952.08 ₹942.66 ₹928.33 ₹918.91 ₹904.58 ₹895.16
Fibonacci ₹952.08 ₹943.01 ₹937.4 ₹928.33 ₹919.26 ₹913.65 ₹904.58
Camarilla ₹939.78 ₹937.6 ₹935.43 ₹928.33 ₹931.07 ₹928.9 ₹926.72

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-11.8%

1 Week

-5.06%

1 Month

+0.41%

3 Months

+6.01%

6 Months

-7.26%

1 Year

-13.6%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹502.76

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

3.39%

Net margin 2.91% × asset turnover 0.5x × equity multiplier 2.33x

Company Overview

Sector

Healthcare

Market Cap

₹14,883 Cr

P/E (TTM)

50.4

ROE

6.53%

Book Value

₹449.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Jubilant Pharmova Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Financial Strength (82/100), while Growth (26/100) is the weakest area to weigh before deciding. Notably: Low return on equity (6.53%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

52/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

82

Growth

26

Valuation

27

Cash Flow

54

Corporate Governance

76

Momentum

42

Institutional Ownership

52

Business Quality

43

Risk & Volatility

62

Liquidity

80

From Screener.in

  • +Company has been maintaining a healthy dividend payout of 43.9%
  • +Company's working capital requirements have reduced from 28.6 days to 13.4 days
  • −The company has delivered a poor sales growth of 6.31% over past five years.
  • −Company has a low return on equity of 4.91% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of earnings webinar for Q2 and H1 FY2027 results uploaded on November 16, 2026.

Q2/H1 FY27 results: revenue up 21%/19%, PAT down; signed MSA, announced CAD 94.5 Mn capex, raised Rs.800 Cr NCDs.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,680 1,677 1,759 1,732 1,752 1,822 1,929 1,901 1,966 2,122 2,290 2,229 2,370
Expenses + 1,438 1,459 1,487 1,480 1,463 1,535 1,584 1,611 1,625 1,833 1,951 1,981 2,130
Operating Profit 242 218 271 252 289 287 345 290 341 289 339 248 240
OPM % 14.0% 13.0% 15.0% 15.0% 17.0% 16.0% 18.0% 15.0% 17.0% 14.0% 15.0% 11.0% 10.0%
Other Income + 19 49 -151 410 8 -10 9 12 4 -19 10 20 14
Interest 66 71 73 71 61 56 53 49 50 56 56 54 58
Depreciation 97 95 101 91 91 91 95 98 105 121 117 127 135
Profit before tax 98 101 -54 500 144 130 206 154 190 93 176 86 62
Tax % 37.0% 34.0% 15.0% 4.0% 29.0% 23.0% 27.0% 34.0% 37.0% 40.0% 32.0% 35.0% 50.0%
Net Profit + 62 66 -62 482 102 101 151 102 120 56 119 56 31
EPS in Rs 4 4 -4 30 6 6 10 6 8 4 8 4 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 5 8 5 9 4 9 10 10 12 17 19 17 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 5,751 5,749 5,861 7,518 9,111 5,976 6,099 6,130 6,282 6,703 7,234 8,280 9,012
Expenses + 5,141 4,493 4,510 5,995 7,367 4,428 4,695 4,980 5,503 5,802 6,061 7,020 7,895
Operating Profit 610 1,256 1,352 1,522 1,744 1,548 1,403 1,150 779 901 1,173 1,260 1,117
OPM % 11.0% 22.0% 23.0% 20.0% 19.0% 26.0% 23.0% 19.0% 12.0% 13.0% 16.0% 15.0% 12.0%
Other Income + 86 4 19 36 -249 225 263 8 -9 -76 416 7 25
Interest 368 371 341 284 220 200 184 145 188 272 240 212 225
Depreciation 288 347 291 415 371 340 349 382 554 382 369 440 500
Profit before tax 40 542 738 859 904 1,233 1,133 630 28 170 981 614 418
Tax % 200.0% 29.0% 22.0% 26.0% 36.0% 27.0% 26.0% 34.0% 333.0% 57.0% 15.0% 35.0% —
Net Profit + -40 387 575 634 577 898 836 413 -65 73 836 398 262
EPS in Rs -4 25 36 40 36 56 52 26 -4 5 53 25 17
Dividend Payout % -83.0% 12.0% 8.0% 7.0% 12.0% 9.0% 10.0% 19.0% -130.0% 102.0% 9.0% 20.0% —
Sales growth 0 0 2 28 21 -34 2 1 2 7 8 14 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 2,438 2,951 3,420 4,071 4,793 5,588 4,726 5,303 5,383 5,418 6,239 7,077 7,139
Borrowings + 4,793 4,493 4,045 3,469 4,840 4,808 2,830 3,192 3,677 3,664 2,731 3,615 4,295
Other Liabilities + 1,372 1,280 1,417 1,902 1,670 1,898 1,192 1,319 1,853 2,240 3,598 4,564 5,215
Total Liabilities 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,830 10,929 11,338 12,584 15,272 16,665
Fixed Assets + 4,911 5,104 5,107 5,401 5,648 6,340 4,609 4,871 5,183 5,091 5,176 6,966 8,250
CWIP 597 611 684 671 901 768 897 1,090 1,562 2,103 3,630 4,040 3,707
Investments 40 85 103 124 115 69 241 239 256 42 44 61 63
Other Assets + 3,071 2,939 3,006 3,262 4,654 5,133 3,017 3,631 3,928 4,101 3,735 4,205 4,645
Total Assets 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,830 10,929 11,338 12,584 15,272 16,665
Equity Capital 16 16 16 16 16 16 16 16 16 16 16 16 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 783 1,099 1,268 1,303 1,122 1,543 1,784 838 661 971 1,072 1,227
Cash from Investing Activity + -362 -309 -465 -614 -1,018 -267 -727 -323 -474 -596 512 -1,143
Cash from Financing Activity + -503 -843 -686 -901 657 -1,050 -1,709 -33 -157 -432 -1,453 95
Net Cash Flow -82 -52 117 -212 761 225 -652 482 30 -58 132 179
Free Cash Flow 434 760 806 819 473 975 1,270 241 -135 83 -38 -120
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 141 91 104 103 84 116 155 90 111 131 112 114

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.67% → 47.67%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Others 0.58% 0.58% 0.58% 0.56% 0.56% 0.56% 0.56% 0.63% 0.57% 0.56% 0.55% 0.55%
Public 25.56% 25.91% 25.18% 25.17% 24.82% 24.48% 24.83% 24.6% 24.57% 24.25% 23.5% 23.38%
Promoters 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 47.67% 47.67% 47.67% 47.67% 47.67% 47.67%
FII 20.29% 19.06% 19.5% 17.94% 16.96% 17.23% 17.4% 16.56% 15.96% 15.9% 15.87% 15.37%
DII 2.89% 3.77% 4.06% 5.66% 6.99% 7.05% 9.52% 10.53% 11.23% 11.63% 12.4% 13.01%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Jubilant Pharmova Ltd (this stock) 14,883 50.4 2.08 6.53%
Vijaya Diagnostic Cen Ltd 14,524 71.3 13.69 18.9%
Indegene Limited 15,640 36.7 4.67 14.4%
Corona Remedies Limited 14,010 63.6 17.34 29.5%
Natco Pharma Ltd. 15,881 19.1 1.5 17.1%
Sudeep Pharma Limited 13,545 71.9 14.14 25.2%
Marksans Pharma Limited 13,347 23.8 4.0 15.2%

Which Mutual Funds Hold Jubilant Pharmova Ltd?

Frequently Asked Questions about Jubilant Pharmova Ltd

Community Sentiment

What are other investors saying about Jubilant Pharmova Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.